Ceftriaxone-Resistant Gonorrhea — China, 2022

  29 March 2024

Gonorrhea, a widespread sexually transmitted infection, is the fourth most common infectious disease in China, with 96,313 cases reported in 2022. The rise in antimicrobial-resistant strains, particularly ceftriaxone-resistant clones, poses a significant challenge to control. The China Gonococcal Resistance Surveillance Program (China-GRSP) monitors antimicrobial resistance, with a significant increase in ceftriaxone resistance from 2017 to 2022. Effective diagnosis, treatment, and sex partner management are crucial to protect infected individuals and prevent ongoing transmission of gonorrhea. Identifying reasons for the spread of ceftriaxone-resistant N. gonorrhoeae in China could guide strategies like antibiotic stewardship to mitigate the rising resistance rate and curb the spread of resistant strains.

 

Further reading: CDC
Author(s): CDC
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed